Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
19,770,250
-
Total 13F shares
-
2,342,780
-
Share change
-
+1,724,704
-
Total reported value
-
$5,992,669
-
Price per share
-
$2.56
-
Number of holders
-
35
-
Value change
-
+$4,499,763
-
Number of buys
-
21
-
Number of sells
-
11
Institutional Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q3 2025
As of 30 Sep 2025,
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) was held by
35 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,342,780 shares.
The largest 10 holders included
MILLENNIUM MANAGEMENT LLC, OAKTREE CAPITAL MANAGEMENT LP, FMR LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, XTX Topco Ltd, BlackRock, Inc., STATE STREET CORP, UBS Group AG, and Oaktree Fund Advisors, LLC.
This page lists
35
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.